Sanofi: strong Q1 performance and 2025 guidance confirmed

On April 24, 2025 Sanofi reported its first quarter 2025 financial results (Press release, Sanofi, APR 24, 2025, View Source [SID1234654329]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Interim Report 1-3/2025

On April 24, 2025 Orion reported interim financial report (Presentation, Orion, APR 24, 2025, View Source [SID1234654277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

On April 24, 2025 Hoffmann-La Roche reported the company continues good momentum into 2025 with 6% (CER) sales growth in the first quarter (Press release, Hoffmann-La Roche, APR 24, 2025, View Source [SID1234654045]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

On April 24, 2025 Hoffmann-La Roche reported the company continues good momentum into 2025 with 6% (CER) sales growth in the first quarter (Press release, Hoffmann-La Roche, APR 24, 2025, View Source [SID1234654044]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Merck Announces First-Quarter 2025 Financial Results

On April 24, 2025 Merck & Co reported its First-Quarter 2025 Financial Results (Presentation, Merck & Co, APR 24, 2025, View Source [SID1234653383]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!